SCHEMBL5537271

SCHEMBL5537271

[O]c1ccc(N2CCC(Nc3ccc(Cl)cc3)CC2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.58
HDAC1 Q13547 1/20 0.57
HDAC8 Q9BY41 1/20 0.57
HDAC6 Q9UBN7 1/20 0.57
MAPT P10636 6/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
MAPK1 P28482 1/20 0.47
CA12 O43570 1/20 0.45
CA2 P00918 1/20 0.45
CA9 Q16790 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
RHOC P08134 1/20 0.44
RHOA P61586 1/20 0.44
FPR2 P25090 2/20 0.43
PROKR1 Q8TCW9 2/20 0.43
NOTUM Q6P988 1/20 0.43
AKR1C3 P42330 1/20 0.43
LMNA P02545 2/20 0.42
CYP1A2 P05177 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5547883 0.87 HDAC1 (0.44) POLBHDAC1HDAC8HDAC6MAPT
SCHEMBL5542047 0.85 DRD2 (0.45) POLBHDAC1HDAC8HDAC6MAPT
SCHEMBL5537275 0.85 CA12 (0.58) POLBHDAC1HDAC8HDAC6MAPT
SCHEMBL5534878 0.84 ME3 (0.47) POLBHDAC1HDAC8HDAC6MAPT
SCHEMBL5535603 0.84 MAPT (0.47) POLBHDAC1HDAC8HDAC6MAPT
SCHEMBL5542611 0.81 CA2 (0.49) HDAC1HDAC8HDAC6MAPTCA12
SCHEMBL14642197 0.81 POLB (0.57) POLBHDAC1HDAC8HDAC6MAPT
SCHEMBL5536635 0.80 MAPT (0.41) HDAC1HDAC8HDAC6MAPTMEN1
SCHEMBL5543622 0.79 HDAC1 (0.41) POLBHDAC1HDAC8HDAC6MAPT
SCHEMBL5544277 0.78 EPHX2 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 POLB 1637/4885HDAC1 322/4885HDAC8 993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.